Wilson’s disease
Authors:
R. Brůha 1; Z. Mareček 4; P. Martásek 2; S. Nevšímalová 3; J. Petrtýl 1; P. Urbánek 4; H. Kalistová 3; L. Pospíšilová 2
Authors‘ workplace:
Univerzita Karlova v Praze, 1. lékařská fakulta, IV. interní klinika VFN
1; Univerzita Karlova v Praze, 1. lékařská fakulta, Klinika dětského a dorostového lékařství VFN
2; Univerzita Karlova v Praze, 1. lékařská fakulta, Neurologická klinika VFN
3; Univerzita Karlova v Praze, 1. lékařská fakulta, Interní klinika ÚVN
4
Published in:
Čas. Lék. čes. 2009; 148: 544-548
Category:
Review Article
Overview
Wilson’s disease is an inherited disorder leading to accumulation of copper in tissues, mainly in the liver and brain. Genetic defect is in the gene coding ATPase type P (ATP7B). The inheritance is autosomal recessive. Up to now, more then 500 mutations causing Wilson’s disease were described. The most frequent mutation in Central Europe is mutation H1069Q.
The manifestation of Wilson’s disease is usually hepatic or neurologic. Hepatic form is manifested by acute or chronic hepatitis, steatosis or cirrhosis. Neurologic involvement is manifested usually after 20 year of age by motor disturbances (tremor, disturbed speech, problems with writing), which could progress into severe extrapyramidal syndrome with tremor, rigidity, dysartria, dysfagia and muscle contracture.
Diagnosis is based on clinical and laboratory examinations (neurologic symptoms, liver disease, low serum ceruloplasmin levels, elevated free copper concentration in serum, high urine copper excretion, and presence of Kayser-Fleischer rings). Confirmation of diagnosis is done by hepatic copper concentration in liver biopsy or by genetic examination.
Untreated disease leads to the death of a patient. Treatment is based on chelating agents decreasing the copper content by excretion into urine (D-penicillamine, trientine) or on agents preventing absorption of copper from food (zinc, ammonium-tetrahiomolybdene). Patients with asymptomatic Wilson’s disease have to be treated as well. In Czech Republic either penicillamine or zinc are used. Liver transplantation is indicated in patients with fulminant liver failure or decompensated cirrhosis.
Screening in families of affected patients (all siblings) is obvious.
Key words:
Wilson’s disease, liver cirrhosis, extrapyramidal syndrome, copper metabolism, penicillamine, zinc.
Sources
1. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Lancet 1912; 1: 1115–1119.
2. Culota VC, Gitlin JD. Disorders of copper transport. In: Scriver CS. TheMolecular and Metabolic Basis of Inherited Disease. New York: McGraw-Hill 2001; 3105–3126.
3. Hellman N, Gitlin JD. Ceruloplasmin metabolism and function. Ann Rev Nutr 2002; 22: 439–458.
4. Klomp AE, Tops BB, van Denberg IE, Berger R, Klomp LW. Biochemical characterisation and subcellular localization of human copper transporter 1 (hCTR1). Biochem J 2002; 364: 497–505.
5. Kelley EJ, Palmiter RJ. A murine model of Menkes disease reveals a physiological function of metallothionein. Nat Genet 1996; 13: 219–222.
6. Rae T, Schmidt P, Pufahl R, Culotta VC, O’Halloran TV. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase. Science 1999; 284: 805–808.
7. Schaefer M, Hopkins R, Failla M, Gitlin JD. Hepatocyte-specific localisation and copper-dependent trafficking of the Wilson’s disease protein in the liver. Am J Physiol 1999; 276: G639–G646.
8. Tanzi RE, Petrukhin K, Chernov I, Pellequer UL, Wasco W, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344–350.
9. Bull AI, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to Menkes gene. Nat Genet 1993; 5: 327–337.
10. Stapelbroek JM, Bollen CW, Ploos van Amstel JK, Erpecum KJ, et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 2004; 41: 758–763.
11. Mareček Z. Wilsonova choroba. Praha: Galén 1996; 143 s.
12. Schiefermeier M, Kollegger H, Madl C, Polli C, Oder W, et al. The impact of apolipoprotein E genotypes on age at onset of symptom and phenotypic expression in Wilson’s disease. Brain 2000; 123: 585–590.
13. Janda J, Kotalová R, Nevoral J, Šuláková T, Smíšek P. Akutní hemolytická krize se selháním jater jako první manifestace morbus Wilson u dětí. Čs Pediat 1996; 51: 509–514.
14. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hematology 2003; 37: 1475–1492.
15. Vrábelová S, Váňová P, Kopečková L, Trunečka P, Smolka V, et al. Molekulární analýza Wilsonovy choroby. Čas Lék čes 2002; 141: 642–645.
16. Vrábelová S, Letocha O, Borský M, Kozák L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab 2005; 86: 277–285.
17. Gojová L, Jansová E, Külm M, Pouchlá S, Kozák L. Genotyping microarray as a novel approach for the detection of ATP7B gene mutations in patients with Wilson disease. Clin Genet 2008; 73: 441–452.
18. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver 2003; 23: 139–142.
19. Wiggelinkhuizen M, Tilanus MEC, Bollen CW, Houwen RHJ. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009; 29: 947–958.
20. Petrášek J, Jirsa M, Šperl J, Kozák L, Taimr P, Špičák J, Filip K, Trunečka P. Revisited Kings’s College score for liver transplantation in adult patients with Wilson’s disease. Liver Transpl 2007; 13: 55–61.
21. Geissler I, Heinemann K, Rohm S, et al. Liver transplantation for hepatic and neurological Wilson’s disease. Transplant Proc 2003; 35: 1445–1446.
22. Wiggelinkhuizen M, Tilanus MEC, Bollen CW, Houwen RHJ. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009; 29: 947–958.
23. Hoogenraad TU. Zinc treatment of Wilson’s disease. J Lab Clin Med 1998; 132: 240–241.
24. Brewer GJ, Dick RD, JohnsonVD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson’s disease with zinc: XV Long-term follow-up studies. J Lab Clin Med 1998; 132: 264–278.
25. Huster D, Leonhardt K, Mossner J. Wilson disease – update on pathophysiology and management. Ces a Slov Gastroent a Hepatol 2008; 62: 220–228.
26. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007; 56: 115–120.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Wilson’s disease
- Health state assessment and rate of working capacity in oncological patients
- A case of acute hepatitis E acquired in the Czech Republic
- „First aid“ for addictive diseases